

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

Global Thematics strategy Short term market rotations are not altering the long term disruption caused by COVID-19

- Global economy re-opening optimism sustained the rotation from growth into value
- We saw a positive contribution from the 'Transitioning Societies' theme
- We added to existing positions with some exposure to the global economy re-opening

Amanda O'Toole

Portfolio Manager, Global Thematics Strategy

What's happening?

Global equity markets rose during March, reflecting growing optimism for normalisation as the vaccine rollout continues. This optimism for the re-opening of the global economy sustained the rotation from growth into value.

Despite ongoing disruption in the US, macroeconomic data has remained positive, with manufacturing and employment data both indicating continued growth, the consumer balance sheet remaining healthy, and plans for fiscal stimulus supportive. Whilst inflation is expected to pick up in the near term, the Federal Reserve has observed that this is likely to be temporary and therefore interest rates are expected to remain low. COVID-19 restrictions have weighed more heavily on economic activity in Europe. In Asia, where the virus has largely been contained, growth remains evident – notably in China, Taiwan and South Korea where manufacturing has recovered well. Policy tightening in China has impacted expectations for the pace of recovery in the region.

We remain convinced that the disruption caused by COVID-19 has accelerated existing secular trends, improving the long-term outlook for a number of themes within the Global Thematics, with the drivers of all five themes remaining intact.

Portfolio positioning and performance

In the context of the market rotation, the strategy underperformed the broader equity market (MSCI All Country World) in March. We saw a negative contribution from four of the five themes, and a positive contribution from the 'Transitioning Societies' theme.

In 'Clean Tech', Darling Ingredients, Waste Connections and Kerry Group all contributed positively in response to strong fundamentals, and some exposure to the re-opening of the global economy. However, this was offset by weakness elsewhere within the theme as a number of outperformers gave back some strength.

In 'Ageing and Lifestyle', weakness came from the London Stock Exchange, Teledoc and Dexcom. All of these holdings have strong fundamentals and a solid long term growth outlook, but suffered as part of the shift into value.



In 'Connected Consumer', the rotation weighed upon outperformers including PayPal and Service Now; partially offset by strength from a number of payments players and from Prologis which provides real estate and logistic equipment for e-commerce.

In 'Automation', holdings in Teradyne and Silicon Labs underperformed. Teradyne provides semiconductor testing services and Silicon Lab is a leading semiconductor player. Both enjoy strong fundamentals associated with automation, electrification and the 5G rollout but the recent weakness seen in the semiconductor sector – due to component shortages – affected those names who gave back some earlier outperformance.

In 'Transitioning Societies', Dr Lal Path Labs which is a leading diagnostics player in India performed well. Recent earnings have demonstrated its exposure to COVID-19 testing, and the recent resurgence in cases has led to expectations of ongoing earnings strength.

We made limited changes to the portfolio during March, trimming outperformers, mostly in 'Connected Consumer' and adding to existing positions with some exposure to the re-opening, including Waste Connections in 'Clean Tech' and Fidelity National Information Services in 'Connected Consumer'.

Outlook

Macroeconomic conditions are mixed as a result of the varying degrees of success in managing COVID-19 and differing levels of policy support during disruption. In Asia, normalisation continues and domestic conditions remain generally healthy, despite the ongoing risk to many export markets and growing concerns for tightening in China. In Europe, COVID-19 restrictions are weighing on macro conditions. The rollout of the vaccine offers some visibility of a path to re-opening the economy and thus provides reason for optimism. Policy support remains strong and fiscal stimulus is expected to be associated with areas of the Global Thematics, including Digitalisation and the Energy Transition. Macro conditions in the US remain stronger, and are supported by the planned fiscal stimulus. This should be positive for equities with a secular growth opportunity.

We retain the view that high quality management teams, operating businesses with a sustainable competitive advantage in their markets and with the benefit of secular tailwinds are well placed to navigate the current disruption. The strategy is therefore well positioned to benefit from the secular shifts we are witnessing globally.

No assurance can be given that the Global Thematics Strategy will be successful. Investors can lose some or all of their capital invested. The Global Thematics strategy is subject to risks including Equity; Emerging markets; Currency; Global investments; Investments in small and/or micro capitalisation universe; ESG.



Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Issued in the U.K. by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

MSCI: Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.